Erythropoietic uroporphyria associated with myeloid malignancy

Summary

Erythropoietic uroporphyria associated with myeloid malignancy (MONDO:0017231) is a disease. A subtype of inherited porphyria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	erythropoietic uroporphyria associated with myeloid malignancy
Mondo ID	MONDO:0017231
Orphanet	280379
UMLS	C5191004
MedGen	1679887
GARD	0010948
Is cancer (heuristic)	no

Disease family

This is a subtype of inherited porphyria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary skin disorder › hereditary photodermatosis › inherited porphyria › erythropoietic uroporphyria associated with myeloid malignancy

Related subtypes (8): erythropoietic protoporphyria, cutaneous porphyria, porphyria due to ALA dehydratase deficiency, chester porphyria, UROD-related inherited porphyria, HMBS-related hepatic porphyria, PPOX-related hepatic porphyria, CPOX-related hereditary coproporphyria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.